A clinical trial is a type of research aimed at evaluating the efficacy and safety of a drug in humans. When we obtain satisfactory results, thousands of people around the world benefit from a new treatment.
At CEMDOE we work together with you to offer you access to innovative treatments that improve your health condition. At the same time, we generate knowledge to provide you with better quality care every day.
Phase 3 study, multicenter, randomized, double-blinded, multicenter study of MK-7684 with pembrolizumab as a coformulation (MK-7684A) versus pembrolizumab monotherapy as first-line treatment in participants with PD-L1-positive metastatic non-small cell lung cancer.
Study population.
Metastatic non-small cell lung cancer with PD-L1 expression (TPS ≥ 1% or ≥ 50%) in first line of treatment.
Stage of disease
Metastatic disease.
Treatment
Pembrolizumab as a coformulation (MK-7684A) vs. pembrolizumab monotherapy
Treatment line
First line
Identification code NCT04738487
Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de Tulisokibart (MK-7240) en participantes con colitis ulcerosa activa de moderada a grave
Población de estudio
Pacientes con colitis ulcerosa activa de moderada a grave
Estadío de enfermedad
Moderada a grave
Tratamiento
Tulisokibart (MK-7240)
Línea de tratamiento
Secundaria
Código de identificación NCT06052059
Download
I want to participate
More information